Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IGM Biosciences Inc IGMS

Healthcare Biotechnology
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites.... see more

Recent & Breaking News (NDAQ:IGMS)

IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

GlobeNewswire September 6, 2023

IGM Biosciences Announces Second Quarter 2023 Financial Results

GlobeNewswire August 3, 2023

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire July 3, 2023

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

GlobeNewswire June 22, 2023

IGM Announces Proposed Public Offering and Concurrent Private Placement

GlobeNewswire June 21, 2023

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

GlobeNewswire June 2, 2023

IGM Biosciences to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

GlobeNewswire May 31, 2023

IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update

GlobeNewswire May 30, 2023

IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2023

IGM Biosciences to Present at Two Upcoming Investor Conferences

GlobeNewswire May 2, 2023

IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days

GlobeNewswire April 19, 2023

IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023

GlobeNewswire April 13, 2023

IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 30, 2023

IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023

GlobeNewswire March 27, 2023

IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference

GlobeNewswire February 2, 2023

IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors

GlobeNewswire January 17, 2023

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

GlobeNewswire January 9, 2023

IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2023

IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting

GlobeNewswire December 11, 2022